N-acetylation and hydroxylation polymorphisms in type II diabetics with microvascular disturbances.
The N-acetylation and hydroxylation (CYP2D6) genetic polymorphisms were assessed in 43 healthy subjects and in 84 type II (non-insulin-dependent) diabetics. The proportions of slow and fast acetylators as well as poor and extensive metabolisers in a group of diabetics suffering from microvascular disturbances (nephropathy, retinopathy and neuropathy) were compared with the control group and with diabetics without such complications. Sulphadimidine was used as a probe for polymorphic acetylation and debrisoquine for CYP2D6. Debrisoquine and its 4-OH metabolite were assayed by means of HPLC, and sulphadimidine using a modified Bratton-Marshall procedure. The frequency of the slow phenotype (63%) was significantly higher in diabetics with microvascular disturbances than in patients without diabetic complications (P < 0.005). In patients with type II diabetes (84), only the extensive phenotype of hydroxylation was observed.
Gawrońska-Szklarz
B
B
Laboratory of Pharmacokinetics and Monitoring Therapy, Medical Academy, Szczecm, Poland.
Górnik
W
W
Pawlik
A
A
Kunicki
P
P
Wójcicki
J
J
Sitkiewicz
D
D
Sych
Z
Z
D000107:Acetylation; D000328:Adult; D000368:Aged; D003647:Debrisoquin; D003924:Diabetes Mellitus, Type 2 / Q000235:genetics* / Q000378:metabolism*; D003925:Diabetic Angiopathies / Q000235:genetics* / Q000378:metabolism*; D005260:Female; D005787:Gene Frequency; D006801:Humans; D006900:Hydroxylation; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D011110:Polymorphism, Genetic / Q000235:genetics*; D013418:Sulfamethazine
D013418:Sulfamethazine; D003647:Debrisoquin